Imagion Biosystems Limited has announced a supplementary prospectus (Supplementary Prospectus) which shall be read with the prospectus dated 28 October 2019 (Prospectus) and issued by Imagion Biosystems Limited (Company or IBX).
Read the supplementary prospectus.
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
November 14, 2024
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority